Isorythm L.P.

Disopyramide phosphate, the active ingredient in Isorythm L.P., is a Class Ia antiarrhythmic presented as an oral tablet for systemic use. It is indicated for patients with life‑threatening ventricular ectopy or persistent atrial fibrillation where other therapies are insufficient. GNH USA supplies Isorythm L.P. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Disopyramide is a Class Ia antiarrhythmic that acts on cardiac electrical activity to treat several arrhythmic conditions.

- Ventricular arrhythmias: reduces the frequency and severity of ventricular premature beats and tachycardia. - Atrial fibrillation: helps restore sinus rhythm and control ventricular response in persistent AF. - Ventricular premature complexes: suppresses symptomatic ectopic ventricular activity.

Disopyramide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: reduced salivary secretion causing discomfort. - Constipation: slowed gastrointestinal motility. - Blurred vision: transient visual disturbances. - Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Proarrhythmia: new or worsening arrhythmias, including torsades de pointes. - Severe hypotension: marked drop in blood pressure leading to syncope. - Heart block: atrioventricular conduction delay or complete block.

When prescribing disopyramide, clinicians should observe several precautionary measures to minimise risk.

- Cardiac monitoring: perform baseline and periodic ECG to detect QT prolongation or new arrhythmias. - Electrolyte balance: correct hypokalemia or hypomagnesemia before initiation. - Renal/hepatic impairment: assess function and adjust dose if necessary. - Concomitant drugs: review for interactions with other antiarrhythmics or CYP3A4 inhibitors. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Disopyramide interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Quinidine: additive antiarrhythmic effect may precipitate severe arrhythmias. - Amiodarone: combined sodium channel blockade increases risk of proarrhythmia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise disopyramide plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely): - Digoxin: may enhance vagal effects, requiring serum level monitoring. - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Diuretics that cause electrolyte loss: monitor potassium and magnesium to avoid arrhythmia exacerbation.